These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18079618)

  • 21. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
    Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
    Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-Line management of CML: a state of the art review.
    Hochhaus A
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S1-S10. PubMed ID: 18397676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
    Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
    Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
    Goldman J
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S11-S13. PubMed ID: 18724281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
    Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Atallah E; Cortes J
    Curr Opin Hematol; 2007 Mar; 14(2):138-44. PubMed ID: 17255791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
    Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
    Scheinfeld N
    J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate: A designer drug.
    Panigrahi I; Naithani R
    J Assoc Physicians India; 2006 Mar; 54():203-6. PubMed ID: 16800347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation.
    Majhail NS; Schiffer CA; Weisdorf DJ
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):789-91. PubMed ID: 16785069
    [No Abstract]   [Full Text] [Related]  

  • 32. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 33. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical decisions for chronic myeloid leukemia in the imatinib era.
    Goldman JM; Marin D; Olavarria E; Apperley JF
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):98-103; discussion 104-13. PubMed ID: 12783383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance and relapse with imatinib in CML: causes and consequences.
    Deininger M
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
    Kujawski LA; Talpaz M
    Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
    Kantarjian HM; Cortes J; Guilhot F; Hochhaus A; Baccarani M; Lokey L
    Cancer; 2007 Apr; 109(7):1365-75. PubMed ID: 17326047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current role of stem cell transplantation in chronic myeloid leukaemia.
    Gratwohl A; Heim D
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):431-43. PubMed ID: 19959092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.